Neostigmina Metilsulfato Medisumi

Myasthenia gravis; paralytic ileus; post-operative urinary retention.

Neostigmina Metilsulfato Medisumimine bromide has a slower onset of effect when given orally than when given parenterally, but the duration of action is longer and the intensity of action more uniform.

To facilitate change of treatment from one route of administration to another, the following doses are approximately equivalent in effect:

0.5 mg intravenously = 1-1.5 mg intramuscularly or subcutaneously = 15 mg orally.

Myasthenia gravis

Adults: Doses of 1-2 tablets by mouth are given at intervals throughout the day when maximum strength is needed (for example, on rising and before mealtimes). The usual duration of action of a dose is two to four hours.

The total daily dose is usually in the range of 5-20 tablets but doses higher than these may be needed by some patients.

Newborn infants: Neostigmina Metilsulfato Medisumimine bromide ampoules are recommended.

Older children: Children under 6 years old should receive an initial dose of half a tablet (7.5 mg) of Neostigmina Metilsulfato Medisumimine Bromide; children 6-12 years old should receive one tablet (15 mg). Dosage requirements should be adjusted according to the response but are usually in the range of 15-90 mg orally per day.

The requirement for Neostigmina Metilsulfato Medisumimine Bromide is usually markedly decreased after thymectomy, or when additional therapy (steroids, immunosuppressant drugs) is given.

When relatively large doses of Neostigmina Metilsulfato Medisumimine bromide are taken by myasthenic patients, it may be necessary to give atropine or other anticholinergic drugs to counteract the muscarinic effects. It should be noted that the slower gastro-intestinal motility caused by these drugs may affect the absorption of oral Neostigmina Metilsulfato Medisumimine bromide.

In all patients the possibility of 'cholinergic crisis', due to overdosage of Neostigmina Metilsulfato Medisumimine bromide, and its differentiation from 'myasthenic crisis', due to increased severity of disease, must be borne in mind. Both types of crisis are manifested by increased muscle weakness, but whereas myasthenic crisis may require more intensive anticholinesterase treatment, cholinergic crisis calls for immediate discontinuation of this treatment and institution of appropriate supportive measures, including respiratory assistance.

Other indications

Adults: The usual dose is 1 to 2 tablets orally.

Children: 2.5-15 mg orally.

The frequency of these doses may be varied according to the needs of the patient.

The elderly: There are no specific dosage recommendations for Neostigmina Metilsulfato Medisumimine bromide in elderly patients.

Neostigmina Metilsulfato Medisumimine Bromide should not be given to patients with mechanical gastro-intestinal or urinary obstruction.

Neostigmina Metilsulfato Medisumimine Bromide is contra-indicated in patients with known hypersensitivity to the drug and to bromides.

Neostigmina Metilsulfato Medisumimine Bromide should not be used in conjunction with depolarising muscle relaxants such as suxamethonium as neuromuscular blockade may be potentiated and prolonged apnoea may result.

Extreme caution is required when administering Neostigmina Metilsulfato Medisumimine Bromide to patients with bronchial asthma.

Care should also be taken in patients with bradycardia, recent coronary occlusion, hypotension, peptic ulcer, vagotonia, epilepsy or parkinsonism.

Not known.

There is no evidence to suggest that Neostigmina Metilsulfato Medisumimine bromide has any special effects in the elderly; however, elderly patients may be more susceptible to arrhythmias than the younger adult.

Side-effects and adverse reactions may include nausea and vomiting, increased salivation, diarrhoea and abdominal cramps.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:www.mhra.gov.uk/yellowcard.

Signs of overdose due to muscarinic effects may include abdominal cramps, increased peristalsis, diarrhoea, nausea and vomiting, increased bronchial secretions, salivation, diaphoresis and miosis. Nicotinic effects consist of muscular cramps, fasciculations and general weakness. Bradycardia and hypotension may also occur.

Artificial ventilation should be instituted if respiration is severely depressed. Atropine sulphate 1 to 2 mg intravenously is an antidote to the muscarinic effects.

Neostigmina Metilsulfato Medisumimine bromide is an antagonist to cholinesterase, the enzyme which normally destroys acetylcholine. The action of Neostigmina Metilsulfato Medisumimine bromide can briefly be described, therefore, as the potentiation of naturally occurring acetylcholine.

Neostigmina Metilsulfato Medisumimine bromide is a quaternary ammonium compound and is poorly absorbed from the gastro-intestinal tract. Following parenteral administration as the methylsulphate, Neostigmina Metilsulfato Medisumimine is rapidly eliminated with a plasma half-life of 50-90 minutes and is excreted in the urine both as unchanged drug and metabolites. It is metabolised partly by hydrolysis of the ester linkage.

Neostigmina Metilsulfato Medisumimine has not been reported to have mutagenic or carcinogenic potential. In rats, acute and chronic exposure causes changes in the fine structure at the end-plate region of muscle.

None known.

None.